{
  "submission_id": 2517,
  "master_form_id": "5c09d8d4-f1e9-4b4d-9b9a-69fde7c6dabe",
  "disease_id": 7,
  "disease_name": "AML",
  "status": "Published",
  "created_on": "2024-09-10T09:07:11.669746Z",
  "subdiseases": [],
  "stagings": [
    {
      "staging_line_id": null,
      "treatment_line_details_id": 0,
      "staging": [
        {
          "stageid": 914,
          "stagename": "Chronic Phase"
        }
      ],
      "treatment_lines": [
        {
          "treatmentlineid": 330,
          "treatmentlinename": "1st Line Maintenance",
          "eligibilities": [
            {
              "id": 138,
              "name": "Aggressive Therapy"
            }
          ],
          "risks": [],
          "mutations": [],
          "drugs": [
            {
              "drug_line_item_id": 0,
              "aon_prefered_name": "AON-PREF Non-VBC",
              "nccn_category_name": "",
              "off_label_name": "OFF-LABEL",
              "aon_prefered_id": 718,
              "nccn_category_id": null,
              "off_label_id": 6,
              "drug_line_string": "74 → 100 or 61",
              "regimen": "this is regimen",
              "misc": "After preoperative systemic therapy if CPS+EG >3, and residual disease. After adjuvant chemotherapy if ≥4 +LN*",
              "drug_classes": [],
              "drug_combinations": [
                {
                  "drug_id": 74,
                  "drug_name": "ADT",
                  "blog_links": [],
                  "brand": null,
                  "drug_item_id": 0
                },
                {
                  "drug_id": 100,
                  "drug_name": "DDMVAC",
                  "blog_links": [],
                  "brand": null,
                  "drug_item_id": 0
                },
                {
                  "drug_id": 61,
                  "drug_name": "durvalumab (IMFINZI)",
                  "blog_links": [],
                  "brand": "ONUREG",
                  "drug_item_id": 0
                }
              ],
              "drug_name_string": [
                "ADT",
                "→",
                "DDMVAC",
                "or",
                "durvalumab (IMFINZI)"
              ],
              "drug_item_id": 0
            },
            {
              "drug_line_item_id": 0,
              "aon_prefered_name": "",
              "nccn_category_name": "",
              "off_label_name": "VBC",
              "aon_prefered_id": null,
              "nccn_category_id": null,
              "off_label_id": 716,
              "drug_line_string": "571",
              "regimen": null,
              "misc": "After preoperative systemic therapy if CPS+EG >3, and residual disease. After adjuvant chemotherapy if ≥4 +LN*",
              "drug_classes": [
                {
                  "drug_class_id": 281,
                  "drug_class_name": "Anti-CD19 CAR T-Cell Therapy",
                  "drug_item_id": 1
                }
              ],
              "drug_combinations": [
                {
                  "drug_id": 571,
                  "drug_name": "ingAdd                    Drug",
                  "blog_links": [],
                  "brand": "",
                  "drug_item_id": 1
                }
              ],
              "drug_name_string": ["ingAdd                    Drug"],
              "drug_item_id": 1
            }
          ],
          "eligibility_combination": "and",
          "mutation_combination": null,
          "treatment_line_details_id": 0,
          "treatment_line_id": 0,
          "stage_line_id": 0
        },
        {
          "treatmentlineid": 715,
          "treatmentlinename": "2nd Line and Beyond",
          "eligibilities": [
            {
              "id": 336,
              "name": "Class A only"
            },
            {
              "id": 385,
              "name": "Clinically Localized (N0M0)"
            },
            {
              "id": 776,
              "name": "Conventional Dose Chemotherapy"
            }
          ],
          "risks": [],
          "mutations": [],
          "drugs": [
            {
              "drug_line_item_id": 0,
              "aon_prefered_name": "",
              "nccn_category_name": "",
              "off_label_name": "VBC",
              "aon_prefered_id": null,
              "nccn_category_id": null,
              "off_label_id": 716,
              "drug_line_string": "123",
              "regimen": null,
              "misc": "After preoperative systemic therapy if CPS+EG >3, and residual disease. After adjuvant chemotherapy if ≥4 +LN*",
              "drug_classes": [],
              "drug_combinations": [
                {
                  "drug_id": 123,
                  "drug_name": "177 lu-dotatate",
                  "blog_links": [],
                  "brand": null,
                  "drug_item_id": 0
                }
              ],
              "drug_name_string": ["177 lu-dotatate"],
              "drug_item_id": 0
            }
          ],
          "eligibility_combination": "and/or",
          "mutation_combination": null,
          "treatment_line_details_id": 0,
          "treatment_line_id": 1,
          "stage_line_id": 0
        },
        {
          "treatmentlineid": 133,
          "treatmentlinename": "Neoadjuvant",
          "eligibilities": [
            {
              "id": 895,
              "name": "Anthracycline And Taxane In Adj Or Met Setting"
            },
            {
              "id": 142,
              "name": "Bortezomib-Refractory"
            },
            {
              "id": 897,
              "name": "Breast Cancer In Males"
            }
          ],
          "risks": [],
          "mutations": [],
          "drugs": [
            {
              "drug_line_item_id": 0,
              "aon_prefered_name": "",
              "nccn_category_name": "",
              "off_label_name": "",
              "aon_prefered_id": null,
              "nccn_category_id": null,
              "off_label_id": null,
              "drug_line_string": "534 → 123 or 541",
              "regimen": null,
              "misc": "",
              "drug_classes": [],
              "drug_combinations": [
                {
                  "drug_id": 534,
                  "drug_name": "ab",
                  "blog_links": [],
                  "brand": null,
                  "drug_item_id": 0
                },
                {
                  "drug_id": 123,
                  "drug_name": "177 lu-dotatate",
                  "blog_links": [],
                  "brand": null,
                  "drug_item_id": 0
                },
                {
                  "drug_id": 541,
                  "drug_name": "azacitidine",
                  "blog_links": [],
                  "brand": null,
                  "drug_item_id": 0
                }
              ],
              "drug_name_string": [
                "ab",
                "→",
                "177 lu-dotatate",
                "or",
                "azacitidine"
              ],
              "drug_item_id": 0
            }
          ],
          "eligibility_combination": "or",
          "mutation_combination": null,
          "treatment_line_details_id": 0,
          "treatment_line_id": 2,
          "stage_line_id": 0
        }
      ],
      "stage_line_id": 0
    },
    {
      "staging_line_id": null,
      "treatment_line_details_id": 0,
      "staging": [
        {
          "stageid": 701,
          "stagename": "Nodal"
        }
      ],
      "treatment_lines": [
        {
          "treatmentlineid": 121,
          "treatmentlinename": "Accelerated",
          "risks": [],
         "mutations": ["HR-", "HER2-" ,"HER2-"],
          "eligibility_combination": "or",
          "mutation_combination": null,
          "treatment_line_details_id": 0,
          "treatment_line_id": 0,
          "stage_line_id": 1
        },
        {
          "treatmentlineid": 396,
          "treatmentlinename": "No Previous Platinum Based Neoadjuvant Therapy",
          "risks": [],
          "mutations": ["HR-", "HER2-"],
          "eligibility_combination": "and/or",
          "mutation_combination": null,
          "treatment_line_details_id": 0,
          "treatment_line_id": 1,
          "stage_line_id": 1
        },
        {
          "treatmentlineid": 392,
          "treatmentlinename": "No Previous Platinum Based Neoadjuvant Therapy",
          "risks": [],
          "mutations": ["HR-"],
          "eligibility_combination": "and/or",
          "mutation_combination": null,
          "treatment_line_details_id": 0,
          "treatment_line_id": 1,
          "stage_line_id": 1
        }
      ],
      "stage_line_id": 1
    }
  ],
  "nccn_notes": "All NCCN recommendations are category 2A unless otherwise indicated",
  "general_notes": null,
  "nccn_version": "2.2024",
  "nccn_date": "2024-08-21T00:00:00Z"
}
